On the Importance of Swiss Patient Data for Pharmaceutical R&D in Switzerland

Rolf Weder and Riccardo Bentele

Working papers from Faculty of Business and Economics - University of Basel

Abstract: Real-world data (RWD) are an increasingly important input into the pharmaceutical R&D process as shown by countries like the USA or Finland. As the availability of and access to Swiss RWD is rather limited, the question arises whether this creates a burden for pharmaceutical R&D in Switzerland. We build on the economics of data and ideas as well as the home-market effect to analyze the importance of local RWD in the three stages of pharmaceutical R&D (pre-clinical, clinical, and post-approval re-search) as well as in the field of personalized medicine. We find qualitative support for a home-market effect and conclude that there is an urgent need to improve the current RWD situation in Switzerland, from the perspective of both Swiss patients and pharmaceutical R&D in Switzerland.

Keywords: Patient Data; Real-World Data; Pharmaceutical R&D; Data and Innovation; Home-Market Effects; International Trade; Location of R&D (search for similar items in EconPapers)
JEL-codes: F1 L65 O3 (search for similar items in EconPapers)
Date: 2024
New Economics Papers: this item is included in nep-hea, nep-ino and nep-tid
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://edoc.unibas.ch/96350/1/WP_Bentele_Weder_Un ... nd_Swiss_RD_2024.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bsl:wpaper:2024/02

Access Statistics for this paper

More papers in Working papers from Faculty of Business and Economics - University of Basel Contact information at EDIRC.
Bibliographic data for series maintained by WWZ ().